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West Nile virus (WNV) infection can cause severe, potentially fatal neurologic illnesses including encephalitis and meningitis (1, 2) . Acute WNV infection also has been associated with acute flaccid paralysis (AFP) attributed to a peripheral demyelinating process (Guillain-Barré Syndrome [GBS]) (3), or to an anterior myelitis (4) . However, the exact etiology of AFP has not been assessed thoroughly with electrophysiologic, laboratory, and neuroimaging data. This report describes six cases of WNV-associated AFP in which clinical and electrophysiologic findings suggest a pathologic process involving anterior horn cells and motor axons similar to that seen in acute poliomyelitis. Clinicians should evaluate patients with AFP for evidence of WNV infection and conduct tests to differentiate GBS from other causes of AFP.
Case Reports
Case 1. In July 2002, a previously healthy man aged 56 years from Mississippi was admitted to a local hospital with a 3-day history of fever, chills, vomiting, confusion, and acute painless weakness of the arms and legs. On physical examination, he had tremor and areflexic weakness in both arms and asymmetric weakness in the legs with hypoactive reflexes; sensation was intact. Laboratory abnormalities included a mildly elevated protein in the cerebrospinal fluid (CSF) ( Table) . An evolving stroke was diagnosed, and the patient was treated with anticoagulant therapy; subsequently, the illness was attributed to GBS, and intravenous immune globulin (IVIG) therapy was initiated. A computerized tomography (CT) scan and magnetic resonance imaging (MRI) of the brain and cervical spine were normal. Electromyography and nerve-conduction studies (EMG/NCS) were indicative of a severe asymmetric process involving anterior horn cells and/or their axons. An acute WNV infection was considered probable on the basis of the presence of virus-specific IgM antibody in serum.
Case 2. In July 2002, a man aged 57 years from Mississippi was admitted to a local hospital with a 3-day history of fever, chills, vomiting, and headache. Laboratory abnormalities indicated an elevated protein and pleocytosis in the CSF (Table) . The patient subsequently had acute respiratory failure requiring intubation. On physical examination, rigidity in all extremities was observed with no spontaneous movement. Following extubation, bilateral facial and areflexic, asymmetric weakness was observed in all extremities; sensory examination was normal. Brain MRI was normal. EMG/NCS were indicative of a severe asymmetric process affecting anterior horn cells and/or their axons. IgM and neutralizing antibody test results confirmed an acute WNV infection.
Case 3. In July 2002, a man aged 56 years from Louisiana with a history of hypertension and coronary artery disease was hospitalized with a 4-day history of fever, vomiting, and painless asymmetric leg weakness. On examination, the patient had a flaccid areflexic right leg and a weak, hyporeflexic left leg; strength and reflexes in the arms were normal. The patient had decreased sensation in a stocking-and-glove distribution and a coarse upper extremity action tremor. A lumbar puncture revealed a CSF pleocytosis (Table) . He was admitted with a diagnosis of postviral demyelination syndrome and treated with antimicrobial medication, IVIG, and dexamethasone. MRI of the spine revealed mild cervical spinal stenosis and homogeneous enhancement of the cauda equina consistent with meningitis. EMG/NCS were indicative of a severe asymmetric process affecting anterior horn cells and/or their axons. IgM and neutralizing antibody test results confirmed an acute WNV infection.
Case 4. In August 2002, a woman aged 69 years from Louisiana with a history of diabetes and degenerative disc disease was hospitalized with a 1-day history of vomiting, lethargy, confusion, fever, and painless right arm weakness. On examination, the patient had nuchal rigidity and a coarse tremor in the chin, left arm, and both legs. The right arm was flaccid and areflexic; strength and reflexes in the other extremities were normal. She was admitted with a diagnosis of meningoencephalitis with associated focal motor radiculitis versus monoplegia secondary to cerebrovascular ischemia. Head CT and brain MRI showed chronic microvascular ischemic changes; MRI of the cervical spine displayed mild narrowing of the spinal cord and the right neural foramina at the C5-6 level. EMG/NCS indicated a severe, asymmetric process affecting anterior horn cells and/or their axons. IgM and neutralizing antibody test results confirmed an acute WNV infection.
Case 5. In August 2002, a previously healthy man aged 50 years from Mississippi was hospitalized with vomiting and headache. He had flaccid, areflexic weakness in the right arm; sensation in all extremities was normal. An acute stroke was diagnosed, and the patient received anticoagulant therapy. EMG/NCS were indicative of a severe, asymmetric process affecting anterior horn cells and/or their axons in the right upper extremity. IgM and neutralizing antibody test results confirmed an acute WNV infection.
Case 6. In August 2002, a man aged 46 years from Louisiana with a history of coronary artery disease was admitted to a hospital with fever, chills, fatigue, and leg weakness. He had a plegic and areflexic right leg and mild left leg weakness; sensation was intact. Laboratory abnormalities included a lymphocytic pleocytosis in CSF (Table) . The patient was admitted with a diagnosis of GBS and treated with IVIG and antibiotics. An enhanced MRI of the spine revealed findings suggestive of meningitis involving the conus medullaris and cauda equina. EMG/NCS indicated a severe, asymmetric process affecting anterior horn cells and/or their axons. IgM and neutralizing antibody test results confirmed an acute WNV infection.
Editorial Note:
The clinical, laboratory, and electrophysiologic findings of these six patients suggest that WNVassociated AFP is a polio-like syndrome with involvement of the anterior horn cells of the spinal cord and motor axons. All six patients had acute onset of asymmetrical weakness without pain or sensory loss. All but one of those with CSF drawn had pleocytosis. Investigation of these patients is continuing.
A polio-like syndrome has been associated with flaviviruses other than WNV (5), and anterior myelitis has occurred with WNV infection (4) . Investigations of primates (6) and other vertebrates infected with WNV have documented involvement of spinal motor neurons and lesions in the ventral gray matter of the spinal cord, with an absence of lesions in peripheral nerves.
Previous case series have attributed WNV infectionassociated AFP to a peripheral neuronal process similar to GBS; acute poliomyelitis might simulate GBS, causing diagnostic confusion (7) . Clinical, laboratory, and electrophysiologic features of these cases might help differentiate poliomyelitis from GBS. In comparison with the asymmetric AFP observed in these patients, GBS syndrome is more often symmetric, generally involves sensory changes or paresthesias, and is associated with an elevation of CSF protein in the absence of pleocytosis. Additional features of typical GBS include an onset several days following signs of acute infection and a generally favorable outcome with rapid improvement in strength. In addition, EMG/NCS typically suggest a predominantly demyelinating picture, or a combined axonal and demyelinating process. A pure motor axonal variant of GBS (8) might be confused with polio; however, this GBS variant is typically characterized by symmetric, distally prominent weakness and subclinical sensory nerve involvement on EMG/ NCS.
Treatment modalities used for patients with GBS include anticoagulation, IVIG, plasmapheresis, and high-dose corticosteroids. These therapies have no beneficial effect for poliomyelitis and can have significant morbidity (9, 10) . In areas where WNV transmission is occurring, clinicians should suspect acute WNV infection and conduct appropriate diagnostic tests in patients presenting with acute, painless, asymmetric weakness, particularly in the setting of an acute febrile illness with CSF pleocytosis. In addition, CSF analysis, thorough EMG/NCS, and neuroimaging should be strongly considered before initiating therapies for GBS or other peripheral inflammatory processes.
Continued surveillance and public health investigation is needed to fully define the scope of neurologic illnesses associated with WNV infection. Health-care providers who are aware of patients with acute WNV infection and AFP should contact their state or local health departments and CDC, telephone 404-639-4657; e-mail, zea3@cdc.gov. 
Human Rabies -Tennessee, 2002
On August 31, 2002, a boy aged 13 years residing in Franklin County, Tennessee, died from rabies encephalitis caused by a rabies virus variant associated with silver-haired and eastern pipistrelle bats. This report summarizes the investigation by the Tennessee Department of Health (TDH). Persons should avoid direct contact with bats, other wildlife, and stray or ill domestic animals; however, if direct contact with bats has occurred, exposed persons should see their health-care provider, and the exposure should be reported to local public health officials.
On August 21, the patient complained of headache and neck pain. The next day, he experienced right arm numbness and weakness and a temperature of 100 º F (37.8 º C). On August 24, the patient was taken to a local hospital emergency department (ED) because of these symptoms and diplopia and was discharged home with a diagnosis of "muscle strain." On August 25, he again sought medical care at the local hospital ED. Symptoms at this time included fever of 102.0 º F (39.0 º C), right arm weakness, slurred speech, diplopia, nuchal rigidity, and dysphagia. The peripheral white blood cell (WBC) count was 10,000/µL (normal: 4.3-11.0/µL) with 83% lymphocytes. Laboratory results from the cerebrospinal fluid (CSF) revealed a WBC count of 220/mL (normal: 0-7/mL) with 80% lymphocytes, a protein concentration of 96 mg/dL (normal: 5-40 mg/dL), and a glucose concentration of 57 mg/dL (normal: 40-80 mg/dL). A computerized tomography scan of the head revealed no focal lesions. The patient was transferred to a regional children's hospital.
On August 26, the patient had difficulty breathing because of decreased mental status and hypersalivation. He was intubated, mechanically ventilated, and sedated because of agitation. Rabies was suspected on the basis of focal neurologic symptoms and hypersalivation, and TDH was notified. The patient's mental status deteriorated rapidly, and by the next morning, he was unresponsive and no longer required sedation. On August 31, the patient was pronounced brain dead, support was withdrawn, and the patient died.
Patient samples, including serum, CSF, saliva, and a nuchal skin biopsy, were collected and sent to CDC on August 27. No rabies virus-specific antibodies were detected in the serum and CSF samples by the indirect fluorescent antibody test. The nuchal skin biopsy was negative for rabies virus antigen by the direct fluorescent antibody test. Additional samples of serum, CSF, and saliva were sent to CDC on August 29. Rabies virus-specific antibody was detected in both the serum and CSF on August 30. The nuchal skin biopsy and saliva from August 29 were positive for rabies virus RNA by reverse transcription polymerase chain reaction. The virus was identified by genetic sequence analysis as a variant associated with silver-haired and eastern pipistrelle bats.
The patient's family had several pets, including cats, dogs, and horses, none of which had been ill. The parents reported that the patient had found a bat on the ground during the day at a nearby lake on approximately July 1 and brought it home. No other family members handled the bat, which was released the same day. The patient never reported being bitten by the bat, but at the time of the investigation the patient could not be asked directly. The family was unaware of any animal bite, and the patient never sought medical counseling or care related to the bat exposure. The family was unaware that bats might be rabid and can transmit rabies virus to humans.
Four household members and one other family member received postexposure prophylaxis (PEP) for rabies because of possible exposure to the virus through contact with the patient's saliva. In addition, 18 health-care workers who had contact with the patient received PEP.
decade (1) . Since 1990, a total of 26 (74%) of the 35 human rabies deaths in the United States have been associated with bat-variant rabies viruses (2) . This is a marked contrast with human rabies cases in Asia, Africa, and South America and with human rabies cases in the United States during the first half of the 20th century, in which canine-variant rabies predominate. It is unclear whether bat-variant human rabies virus cases have increased over time or whether more focused surveillance efforts have detected bat-variant rabies more effectively.
Issues of transmission and exposure are more complicated in bat-variant rabies than in terrestrial carnivore-variant rabies. Of the 26 human cases of bat-variant rabies in the United States since 1990, only two had known animal bites. Possible reasons for the cryptogenic nature of transmission of bat-variant rabies include 1) lack of knowledge by the general public that bats might be rabid and can transmit the virus to humans; 2) limited pain and injury inflicted by bites from the relatively small jaws and teeth of bats; and 3) viral mechanisms that might increase virulence, including increased epithelial cell tropism and muted antigenic response associated with silver-haired/eastern pipistrelle bat-variant rabies virus (3) . Because the majority of human cases of bat-variant rabies lack a history of a known bite, PEP not only is indicated in the setting of a recognized bite but also might be considered in situations in which there is a reasonable possibility that a bite has occurred. The Advisory Committee on Immunization Practices (ACIP) has outlined specific bat exposure scenarios for which PEP should or should not be recommended (4). Experienced emergency-medicine physicians, infectious disease consultants, and public health officials can provide advice on using PEP for persons with complicated exposure histories.
Bat rabies has been documented throughout the continental United States. Prevention of human cases of bat-variant rabies is complicated by the cryptogenic nature of many exposures. However, certain prevention guidelines should be followed. The public should be informed that bats carry the rabies virus. Unvaccinated or untrained persons should not handle bats unless necessary. If necessary, protective gloves and safety precautions should be used. Bats are not appropriate as pets. Bats should be excluded from buildings and other structures in close proximity to humans. In cases of known or possible exposure to a bat, timely submission of the bat to public health officials facilitates testing for the presence of rabies virus, helps to ensure rapid PEP when indicated, and minimizes the unnecessary use of an expensive therapy.
Carbon monoxide (CO) is an odorless, colorless gas produced from the incomplete combustion of carbon-based fuels such as gasoline or wood. In the United States, CO poisoning causes approximately 500 unintentional deaths each year (1) . Although CO poisonings often have been reported to occur in enclosed and semi-enclosed environments (2), they can also occur in open-air environments (3, 4) . This report describes two related cases of CO poisoning that occurred in children who were participating in recreational activities on a ski boat. Recreational boaters should be aware of the dangers of open-air CO poisoning, and engineering solutions are needed to reduce the amount of CO in boat exhaust.
On June 1, 2002, a family of two adults and three children (two boys aged 4 and 12 years and a girl aged 2 years) and three friends went to a lake in Georgia to water ski. The ski boat was placed in an idling position while one parent put on a ski vest. During this time, the girl climbed over the back of the boat onto the swim platform (a wooden platform attached to the stern a few inches above the surface of the water) and lay in a prone position to push back and kick the water. In <1 minute, she became unconscious and unresponsive.
The girl's father, a family physician, observed that her pupils were constricted and her jaw was firmly clenched. She had a pulse but no chest movement. He performed rescue breathing; after 15-20 assisted ventilations, the child resumed unassisted breathing. Local emergency medical services (EMS) personnel were notified. Approximately 35 minutes later, EMS personnel arrived and started the child on 100% oxygen through a nonrebreather mask and transported the child to the local hospital. Nearly 3 hours after exposure, the child's carboxyhemoglobin (COHb) level was 14.3% (normal: <5.0%). Back calculations of COHb levels estimated that her COHb level was 50%-57% immediately after exposure on the swim platform.
During the initial resuscitation of the girl, her youngest brother was removed from the swim platform and watched by friends during his sister's transport to the hospital. Several hours after being removed from the water, he complained of severe headache, vomited, and fell asleep. He was transported to the hospital for evaluation. Approximately 4 hours after exposure, his COHb level was 10.1%. Back calculations of COHb levels estimated that the boy's COHb level was 18%-21% immediately after exposure. Both children were transported to another hospital, admitted to the pediatric intensive care unit, and treated with 100% oxygen. They were discharged the following day.
Editorial Note: Open-air CO-related morbidity and mortality has been reported to occur with exposure to exhaust from gasoline-powered electricity generators on houseboats (3). However, this report describes CO poisoning resulting from direct exposure to CO in the exhaust of a ski boat. Ambient CO concentrations have been measured as high as 27,000 parts per million (ppm) in the stern of boats involved in CO-poisoning fatalities (5) . In comparison, the World Health Organization has set a ceiling limit on a person's exposure to CO at 87 ppm during a 15-minute interval (6) . Although the introduction of the catalytic converter to automobiles reduced CO concentrations in automobile exhaust by >90% (7), emissions-control devices have not been introduced to the propulsion engines of recreational boats.
Since 1990, a case listing compiled by an interagency working group consisting of the U.S. Department of the Interior, National Park Service, CDC's National Institute for Occupational Safety and Health, and the U.S. Coast Guard has documented 17 fatalities and 37 nonfatal poisonings on U.S. waters resulting from exposure to the propulsion engine exhaust of ski boats and cabin cruisers (5) . Although many poisoning victims were exposed while on or near the swim platform, several fatalities also occurred among persons seated in the stern of the boat. This case listing was compiled from media reports and probably underrepresents the national burden of these incidents. In addition, because COHb measurements are obtained infrequently from victims of unwitnessed drownings (8) , the actual number of drownings resulting from CO poisoning remains unknown.
On inhalation, CO binds to hemoglobin with a binding affinity 200-270 times greater than that of oxygen. At COHb concentrations of 10%-20%, symptoms of CO poisoning might resemble those of motion sickness or heat exhaustion and can include headache, nausea, dizziness, and vomiting. Although seizures, coma, and death might occur at COHb concentrations >30% (9), COHb concentrations of >50% have been found after minutes of outdoor exposure to boat exhaust (5) . Health-care providers should consider immediate COHb measurements any time a drowning occurs near a boat or boat occupants present with signs and symptoms consistent with CO poisoning.
Recreational boaters should be aware that boat exhaust can flow back into the rear of the boat and that CO in the exhaust is undetectable because it is odorless and colorless. In addition, they should avoid swimming or body surfing near the exhaust system while the boat or generator is running. Studies of CO concentrations in the air around boats and of COHb levels in recreational boaters are needed to determine the extent of boat-related CO poisonings, and public health campaigns to warn of the danger of boat-related CO poisonings require further evaluation. The use of emissions-control devices in recreational boats can reduce CO emissions and the risk for CO poisoning.
Progress Toward Poliomyelitis Eradication -India, Bangladesh, and Nepal, January 2001-June 2002
Since the World Health Assembly resolved in May 1988 to eradicate poliomyelitis, the estimated incidence of polio has decreased >99%, and three World Health Organization (WHO) regions (American, Western Pacific, and European) have been certified polio free (1) . Member countries of the South-East Asia Region (SEAR)* of WHO began accelerating polio eradication activities in 1994 and since then have made substantial progress toward that goal (2) . By January 2001, indigenous wild poliovirus transmission in SEAR was limited to northern India, with ongoing poliovirus transmission posing a continuing threat to Bangladesh and Nepal. This report summarizes progress towards polio eradication in India, Bangladesh, and Nepal during January 2001-June 2002 and highlights the remaining challenges to eradicating polio in these countries.
Routine Immunization
According to official government estimates, 70% of infants aged <1 year in India, 66% in Bangladesh, and 92% in Nepal received 3 doses of oral poliovirus vaccine (OPV) during 2001. National aggregate data might not reflect substantial in-country variation and are not necessarily verified by accurate surveys. 
Supplementary Immunization Activities
Acute Flaccid Paralysis Surveillance
Acute Flaccid Paralysis (AFP) surveillance in India, Bangladesh, and Nepal is facilitated through a network of surveillance medical officers (SMOs) who receive special training and are responsible for assisting the local health authorities in a defined area. As of June 2002, India had 239 SMOs, Bangladesh had 33, and Nepal had 14. This system has been supported in Bangladesh and Nepal by Stop Transmission of Polio (STOP) teams ** .
Since 2000, India, Bangladesh, and Nepal have exceeded the WHO-established target for a nonpolio AFP rate indicative of sensitive surveillance (i.e., >1 per 100,000 population aged <15 years) and met the WHO target measure of timeliness and completeness of stool specimen collection (i.e., >80%) (Table) . As of June 2002, a total of 10 Indian states (accounting for 15% [approximately 151 million persons] of the country's total population) had nonpolio AFP rates of <1 per 100,000 population aged <15 years. Six Indian states (accounting for 8% [approximately 80 million persons] of the country's population) had inadequate stool specimen collection rates (i.e., <80%). During 2001, the nonpolio enterovirus isolation rate (target: >10%), a marker of laboratory performance and the integrity of the reverse cold chain for specimens, was 10%-30% in different laboratories (total: eight laboratories) of India, 29% in Bangladesh, and 29% in Nepal.
Wild Poliovirus Incidence
Since the last wild poliovirus positive cases occurred in Bangladesh (August 2000) and Nepal (November 2000), India has been the only country in SEAR with indigenous *Bangladesh, Bhutan, Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, and Thailand. † Nationwide mass campaigns during a short period (days to weeks) in which 2 doses of OPV are administered to all children (usually aged <5 years), regardless of previous vaccination history, with an interval of 4-6 weeks between doses. § Mass campaigns same as NIDs but limited to parts of a country. ¶ In India, mopping-up activities are mass campaigns in selected areas conducted in response to isolation of wild poliovirus, with emphasis on door-to-door vaccination. ** Groups of international health-care professionals deployed to a local area for 3 months to assist health ministry staff. (from four to three); all cases observed during 2001 were attributable to one of these six remaining lineages, and no new lineages were identified. Surveillance data indicate that two northern states, Uttar Pradesh (UP) and Bihar, are the remaining endemic foci responsible for continuing circulation in India. Although wild poliovirus was isolated from a total of 63 districts in 11 Indian states in 2001, the majority were reported from these two states: 216 (81%) cases in UP and 27 (10%) in Bihar. As of June 2002, of the 159 cases reported from 50 districts in eight states, 135 (85%) were reported from UP and nine (6%) from a small cluster in Bihar. In UP, a large outbreak related to a single P1 strain has spread to new areas in central and eastern UP; P3 lineages were detected only in western UP. All cases identified in the other six states belong to P1 lineages indigenous to UP and Bihar and are considered importations from these areas. however, the spread of wild poliovirus to districts of UP without endemic transmission and to other states in India indicates the urgency of implementing SIAs with improved quality. The principal reasons for failure to vaccinate children during vaccination campaigns are 1) vaccination teams not identifying all eligible children, 2) poor or nonexistent supervision in many areas, and 3) poor participation of families in underserved communities. High population density, poor sanitation and hygiene, and low routine vaccination coverage in these areas greatly favor transmission of wild poliovirus, and high birth rates leave large cohorts of children unvaccinated.
The basic strategies of AFP surveillance and intensive OPV campaigns to supplement routine vaccination programs have been proven successful in eradicating polio in nearly all states of India, the other nine countries of SEAR, and other countries worldwide (3). To interrupt transmission in northern India, innovative measures are needed to increase community involvement and improve the quality of SIAs. On the basis of an analysis of standardized independent observer checklists and program management reviews, many new approaches were implemented in India during January 2001-June 2002. These included 1) deploying follow-up vaccinator teams to find and vaccinate children missed by primary teams; 2) increasing the number of SMOs working in high-risk districts; 3) changing the ratio of supervisors to vaccination teams from one to five during SIAs to one to three in selected high-risk areas; 4) creating a network of social mobilization persons at the district, block, and village levels to generate demand and promote acceptance of vaccination; 5) retraining vaccinators and supervisors to improve interpersonal communication skills; 6) forming a National Operations Group comprising the Ministry of Health and national and international partners to facilitate rapid implementation of strategic decisions; and India will continue to monitor the impact of these interventions during SNIDs that are planned to cover UP, Bihar, and parts of five other high-risk states † † 
Progress towards polio eradication in India, Bangladesh, and Nepal is the result of substantial investments made by these countries and the international polio eradication partnership. The eradication initiative in SEAR is close to achieving its goal, and all groups involved should intensify their efforts to ensure success. This will require continuing political commitment and effective acceleration of strategies to reach every child during the planned immunization rounds, particularly in northern India. organs were the source of infection for the four organ recipients, the source of the organ donor's infection remains unknown; an investigation of the numerous transfusions received by the organ donor is ongoing. Since the report of these cases, CDC has been informed of other patients with suspected WNV-associated meningoencephalitis (WNME) after receiving blood products within 4 weeks of illness onset. One of these patients also received an organ transplant. All of these patients resided in areas with epidemic and epizootic WNV activity; investigations are ongoing to determine whether transfusion or transplantation was the source of WNV transmission. This report summarizes two investigations of recipients of organs and blood products, four investigations of transfusion recipients, and one investigation of a WNV-seronegative person with fever and encephalopathy who received a potentially contaminated unit of blood. Investigation 1. On August 1, four organs were recovered from an organ donor and were transplanted into four persons (1, 2) . WNME was confirmed in three recipients and WNV fever in one recipient (Table) . Illness began 7-17 days after transplantation. Although a sample of the donor's plasma collected at the time of the organ recovery was positive for WNV by kinetic quantitative PCR assay (TaqMan ® ), the source of the organ donor's infection is unknown. During treatment for injuries, which eventually were fatal, the organ donor received blood products from 63 unique donors. Donor follow-up has been initiated by the blood collection agency. Of 41 donors for whom retention segments* were available, 22 tested negative for WNV by TaqMan ® and serology, and 19 tested negative for WNV by TaqMan ® ; serology testing on these 19 segments is in progress. In addition to the organ donor, 35 other persons received components derived from these 63 donors; follow-up of these recipients is pending. Untransfused components are being returned to the blood collection agency. One has tested negative for WNV by TaqMan ® ; testing on the others is under way.
Investigation 2. A man aged 47 years received a liver transplant on August 14 and during the next 7 days received 39 units of blood products. After discharge on August 24, he was readmitted to the hospital on September 3 with fever and subsequently developed encephalopathy. A lumbar puncture revealed elevated protein, a lymphocytic pleocytosis, and WNV IgM antibody; the patient recovered and was discharged. Before organ recovery, the donor received two units of albumin and one unit of fresh frozen plasma (FFP). In addition to the liver, two kidneys were recovered and were transplanted into one recipient, whose clinical status is being investigated.
Investigation 3. During July 27-28, a woman aged 24 years received 18 units of blood products (12 units of packed red blood cells [PRBC] and six units of FFP) because of postpartum hemorrhage. On August 1, she was discharged. The patient developed worsening headache and fever and 22 days later was readmitted to the hospital with meningitis. A lumbar puncture revealed a lymphocytic pleocytosis; serum and CSF samples were positive for WNV by IgM. Retention segments were available from 15 of the 18 donations administered in July; three (20%) were positive for WNV by * Blood samples from tubing that had been attached to the original donor collection bag.
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TaqMan ® . Of three components derived from a donation associated with these positive segments, one unit of FFP was retrieved, tested, and found to be positive for WNV by TaqMan ® ; viable WNV also was isolated from this plasma. The donor of this blood component sought medical care 4 days after donation because of fever, chills, and headache; follow-up WNV-antibody testing of this donor is in progress. Investigation 4. A man aged 72 years with a history of myelodysplasia and frequent blood transfusions received four units of PRBC during July 18-August 7. The patient was admitted on August 8 with generalized weakness and fever. A serum sample obtained 2 days later was positive for WNV by IgM. No retention segments were available. Of five components derived from these four donations, four units of FFP were retrieved, and testing is in progress. One unit of platelets was transfused into another recipient, and follow-up is pending.
Investigation 5. On July 17, a woman aged 78 years received two units of PRBC 1 day after a surgical amputation. Three days after receiving the transfusions, she developed fever, altered mental status, and seizures. Acute-and convalescent-phase serum samples and CSF were positive for WNV by IgM. Retention segments associated with both units of PRBC were negative for WNV by TaqMan ® and by IgM. Follow-up of the two donors and a patient who received platelets from one of these donors is in progress.
Investigation 6. During July 26-August 23, a man aged 77 years who required frequent blood transfusions for myelodysplasia received eight units of blood products (four units of PRBC and four units of single-donor platelets). On August 23, the patient developed fever and headache. Serum and CSF samples were positive for WNV-specific IgM. The patient had progressive encephalopathy and died. Four retention segments were available for four of the eight donations; all were negative for WNV by TaqMan ® . Follow-up is ongoing for three patients who received platelets from three of the eight donors. In addition, four units of plasma have been withdrawn and are being tested. Investigation 7. On July 26, a woman aged 55 years received three units of PRBC after an orthopedic procedure. The following day, she developed fever and encephalopathy. Serum samples collected on the fourth and 40th days after illness onset were negative for WNV by IgM. Retention segments were available from all donations; two were negative for WNV by TaqMan ® . One was positive for WNV by TaqMan ® but negative for WNV-specific IgM; serum collected from the donor 69 days after donation was positive for WNV-specific IgM, reflecting WNV seroconversion. The donor denied fever, headache, or other symptoms during the 3 weeks before or after the donation. A patient undergoing cardiac surgery received a unit of FFP from this donation. A serum sample collected from this patient was negative for WNV by IgM. Follow-up serum samples are being collected for the index case and for the recipient of the FFP.
Editorial Note: CDC, FDA, HRSA, blood collection agencies, and state and local health departments continue to investigate possible transmission of WNV through blood transfusion or organ transplantation. The initial investigation demonstrated transmission from a WNV-viremic organ donor to four recipients of those organs. In another investigation (Investigation 3), the isolation of live WNV from a unit of FFP indicates that the virus can survive in some blood components and probably can be transmitted by transfusion. Although this case is highly suspicious for transfusionassociated transmission, this patient lived in an area where WNV was active, and the exact means of WNV acquisition cannot be determined. In contrast, the preliminary results of another case investigation (Investigation 7) indicate that not all recipients of potentially WNV-contaminated units (i.e., those that are positive for WNV by TaqMan ® ) will become infected with WNV.
The Public Health Service (PHS) recommends several precautionary measures to reduce the possible risk for WNV transmission by organ transplantation or blood transfusion. Patients with WNV infection who have received blood transfusions or organs within 4 weeks preceding symptom onset should be reported to CDC through local public health authorities to initiate an investigation. Serum or tissue samples should be retained for later studies. In addition, patients with WNV infection who have onset of symptoms within 1 week of blood 
(1) (6) (1) † (1) or organ donation should be reported. Prompt reporting of these persons will facilitate withdrawal of potentially infected blood components. HRSA has alerted organ transplant organizations about the potential for transplantation-associated WNV infection.
Tests for WNV suitable for routine blood donor screening are not available. However, FDA is working with public and private partners to facilitate development of such tests to ensure their availability if screening is necessary. FDA is developing additional guidance for blood centers to enhance reporting of post-donation illnesses suggestive of WNV infection and to determine when retrieval of recent blood collections from these donors is warranted.
Approximately 4.5 million persons receive blood or blood products annually. Although persons needing blood transfusions or organ transplants should be aware of the risk for WNV infection, the benefits of receiving needed transfusions or transplants outweigh the potential risk for WNV infection. In addition, blood donation poses no risk to the donor for acquiring WNV, and PHS encourages blood donation. 
West Nile Virus
United States
During the reporting period of September 12-18, a total of 440 laboratory-positive human cases of WNV-associated illness were reported from Illinois (n=107), Ohio (n=76), Michigan (n=50), Indiana (n=36), Missouri (n=23), Mississippi (n=22), Texas (n=17), Louisiana (n=16), New York (n=13), Georgia (n=11), Iowa (n=10), Kentucky (n=eight), Nebraska (n=eight), Alabama (n=seven), Virginia (n=six), Minnesota (n=five), North Dakota (n=five), South Dakota (n=five), Connecticut (n=three), Tennessee (n=three), Florida (n=two), Massachusetts (n=two), Pennsylvania (n=two), Colorado (n=one), New Jersey (n=one), and Oklahoma (n=one). During this period, Colorado reported its first human WNV case ever. During the same period, WNV infections were reported in 525 dead crows, 509 other dead birds, 552 horses, and 399 mosquito pools.
During 2002, a total of 1,641 human cases with laboratory evidence of recent WNV infection have been reported from Illinois (n=399), Louisiana (n=238), Ohio (n=169), Michigan (n=166), Mississippi (n=144), Missouri (n=98), Texas (n=84), Indiana (n=78), New York (n=35), Tennessee (n=26), Nebraska (n=23), Alabama (n=21), Kentucky (n=20), South Dakota (n=18), Georgia (n=17), Minnesota (n=13), Iowa (n=11), Virginia (n=11), Wisconsin (n=11), Massachusetts (n=nine), North Dakota (n=nine), Florida (n=eight), Arkansas (n=six), Connecticut (n=six), Maryland (n=five), Oklahoma (n=four), the District of Columbia (n=three), New Jersey (n=three), Pennsylvania (n=three), California (n=one), Colorado (n=one), and South Carolina (n=one) (Figure 1 ). Among the 1,371 patients with available data, the median age was 55 years (range: 3 months-99 years); 731 (53%) were male, and the dates of illness onset ranged from June 10 to September 11. A total of 72 human deaths have been reported. The median age of decedents was 79 years (range: 42-99 years); 42 (58%) deaths were among men. In addition, 4,562 dead crows and 3,366 other dead birds with WNV infection were reported from 42 states, New York City, and the District of Columbia; 2,244 WNV infections in mammals (all equines) have been reported from 31 states (Alabama, Arkansas, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Minnesota, Mississippi, Missouri, The 133 patients had a median age of 61 years (range: 9-98 years); 71 (53%) were male. The median age for 29 patients with known diagnosis of either aseptic meningitis (17 cases), encephalitis (10 cases), meningo-encephalitis (one case) or acute flaccid paralysis (one case) was 52 years (range: 9-86 years); 14 (48%) were male. The median age of the seven decedents was 79 (range: 68-88 years) years; five (71%) were men. Onset of symptoms of WNV infection among reported patients occurred during July 27-September 8. All cases remain under investigation.
Human cases have occurred among residents of 20 counties (Figure 2) , with 96 (72%) cases reported from the most populated county in Ohio, Cuyahoga County, which includes Cleveland with 32 cases. The attack rate during January 1-September 12 was 1.2 per 100,000 for the state population, 7.0 for Cuyahoga County, and 6.7 for Cleveland.
Of Ohio's 88 counties, 87 (99%) reported WNV activity in horses, birds, or mosquitoes. The first bird tested positive on May 19. Of the 1,643 dead birds tested, 855 (52%) have tested positive for WNV by polymerase chain reaction. Mosquito pools began testing positive on May 28. Through September 11, a total of 1,018 mosquito pools have tested positive, and 133 horses from 49 counties have tested laboratory positive. Public health authorities plan to continue surveillance for human and equine cases through October.
The Ohio WNV Work Group comprises representatives from the departments of Health, Agriculture, Environmental Protection, and Natural Resources and coordinates surveillance and response activities. Ohio has a program for technical support of public agencies performing mosquitomanagement services. The established partnership between the Ohio Mosquito Control Association, ODH, the Ohio Pest Control Association, the Ohio State University Extension, and local mosquito-control agencies provided training to persons with an interest in mosquito management. ODH helps local governments establish mosquito-management programs.
Ohio's prevention activities include risk communication and informing the public about how to avoid exposure through source reduction and personal protection. Pamphlets, fact sheets, and posters have been disseminated through local health departments. ODH also established the WNV Telephone Information Line to handle questions from the public. During August 1-September 12, a total of 3,884 phone calls were received.
Additional information about WNV activity in Ohio is available at http://www.odh.state.oh.us. Additional information about WNV activity is available from CDC at http:// www.cdc.gov/ncidod/dvbid/westnile/index.htm and http:// www.cindi.usgs.gov/hazard/event/west_nile/west_nile.html. 
